Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine September 2017, 58 (9) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

Is tau upside-down 18F-FDG? van Eimeren and colleagues highlight areas in which tau imaging may offer additional clinical value to that of 18F-FDG PET in elucidating mechanisms of neurodegeneration.

Page 1357

Pediatric PET/CT: Fahey and colleagues offer an educational overview of factors that affect CT radiation dose, ways that CT is used in the context of PET/CT, and approaches to integrating PET/CT and diagnostic CT in children.

Page 1360

Optical imaging of human organoids: Walsh and colleagues describe primary tumor organoids as a model for use in cancer research and as a platform for drug screening with optical metabolic imaging, which can probe organoid cells for drug-resistant subpopulations.

Page 1367

64Cu-DOTA-alendronate breast imaging: Ahrens and colleagues evaluate this tracer as a microcalcification-targeting PET imaging agent in a rat model, with a long-term goal of differentiating malignant from benign lesions.

Page 1373

Brachytherapy with 90Y-polyoxazoline: Sano and colleagues report on brachytherapy using biocompatible, injectable thermoresponsive polymers that can self-aggregate above a specific transition temperature, resulting in long-term intratumoral retention of radioactivity.

Page 1380

89Zr-DFO-AMG102 for HGF: Price and colleagues detail synthesis, radiolabeling, and in vitro and in vivo validation of this new immuno-PET imaging agent, which accumulates selectively in tumors with high local levels of hepatocyte growth factor protein.

Page 1386

Cerenkov radiation–induced PIT: Nakamura and colleagues demonstrate the feasibility of using Cerenkov radiation generated by 18F-FDG accumulated in tumors to induce photoimmunotherapy.

Page 1395

GRPR expression in breast cancer: Morgat and colleagues screen a large number of invasive breast cancers with immunohistochemistry for the presence and intensity of gastrin-releasing peptide receptor expression, a potentially valuable treatment target.

Page 1401

99mTc-trofolastat SPECT/CT in PCa: Goffin and colleagues assess the SPECT performance of this small-molecule inhibitor of prostate-specific membrane antigen in patients with intermediate- and high-grade prostate cancer before radical prostatectomy and pelvic lymph node dissection.

Page 1408

PET after anal cancer treatment: Houard and colleagues report on the relevance of 18F-FDG PET/CT as a strategy for response evaluation, including predictive value, after chemoradiation for anal cancer.

Page 1414

PET/CT and immune checkpoint blockade: Cho and colleagues describe the utility of 18F-FDG PET/CT imaging as an early predictor of response to immune checkpoint inhibitors in patients with advanced melanoma.

Page 1421

Variability of response measurement: O and colleagues look at interobserver variability in quantitative 18F-FDG PET/CT parameters used in assessments of oncologic treatment response across multiple sites and readers.

Page 1429

SSTR antagonists: Nicolas and colleagues investigate the biodistribution, pharmacokinetics, SPECT/CT characteristics, and dosimetry of a somatostatin receptor 2 antagonist labeled with 177Lu, 90Y, and 111In and compare these with 177Lu-DOTATATE.

Page 1435

PSMA therapeutics: Kelly and colleagues report on new dual-target small molecules with high-affinity targeting to prostate cancer cells through interaction with prostate-specific membrane antigen and moderate affinities for albumin, with potential for use in targeted α-therapy.

Page 1442

Perspective on 68Ga-DOTATOC imaging: Mailman provides retrospective highlights and a patient’s viewpoint on development of PET/CT imaging in neuroendocrine tumor therapy and introduces an article on this topic in this issue of JNM.

Page 1450

68Ga-DOTATOC imaging: Graham and colleagues report on the results of a systematic review and meta-analysis of the efficacy of this somatostatin receptor–targeted ligand for several distinct indications, with data in support of U.S. FDA approval.

Page 1452

Predictive CZT SPECT: Engbers and colleagues determine the prognostic value of myocardial perfusion imaging with a cadmium-zinc-telluride SPECT camera in a large cohort of patients with suspected coronary artery disease.

Page 1459

Initial evaluation of 11C-preladenant: Sakata and colleagues describe first-in-human studies of safety, radiation dosimetry, and imaging with this selective antagonist for mapping of cerebral adenosine A2A receptors with PET.

Page 1464

Impaired CSF clearance in AD: de Leon and colleagues use dynamic PET with 18F‐THK5117, a tracer for tau pathology, to estimate ventricular cerebrospinal fluid time–activity as a biomarker for CSF clearance in Alzheimer disease.

Page 1471

TSPO PET in MS: Datta and colleagues use PET with translocator protein radioligands to assess microglial activation in lesions and in normal-appearing white matter in patients with multiple sclerosis.

Page 1477

AV45 kinetic modeling vs. static imaging: Ottoy and colleagues compare the SUV ratio method for 18F-AV45 uptake quantitation on PET with the gold standard volume of distribution to assess differences in plaque load in elderly patients.

Page 1483

PET and anticonvulsant-induced cognitive impairment: Zhu and colleagues explore correlations between monoamine receptor PET imaging and additional imaging and clinical assessments in patients after anticonvulsant therapies, emphasizing the role of monoamine receptor dysfunction in anticonvulsant-induced cognitive impairment.

Page 1490

18F-THK-5351 radiation dosimetry: Hsiao and colleagues estimate in humans the radiation dose of this novel radiotracer with high binding selectivity for tau and compare clinical radiation dosimetry results with previous preclinical data.

Page 1498

PET/CT in S. aureus bacteremia: Berrevoets and colleagues investigate the utility of 18F-FDG PET/CT in patients with Staphylococcus aureus bacteremia, with a focus on detection of metastatic infection and consequences for treatment and outcome.

Page 1504

Next-generation PET/CT system: Hsu and colleagues detail system performance studies for the Discovery MI PET/CT system, a new time-of-flight system based on silicon photomultipliers.

Page 1511

PET/MR for oncologic brain imaging: Rausch and colleagues compare standard MR-based attenuation correction for PET/MR imaging with a model-based approach for the Siemens mMR PET/MR system.

Page 1519

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (9)
Journal of Nuclear Medicine
Vol. 58, Issue 9
September 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Sep 2017, 58 (9) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Sep 2017, 58 (9) 8A;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • 11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis
  • Diagnostic PET Imaging of Mammary Microcalcifications Using 64Cu-DOTA-Alendronate in a Rat Model of Breast Cancer
  • 18F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality
  • Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
  • Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET
  • Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
  • Role of 18F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma
  • Validation of the Semiquantitative Static SUVR Method for 18F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function
  • Cerenkov Radiation–Induced Photoimmunotherapy with 18F-FDG
  • Operational and Dosimetric Aspects of Pediatric PET/CT
  • 89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection
  • Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
  • PET/MRI for Oncologic Brain Imaging: A Comparison of Standard MR-Based Attenuation Corrections with a Model-Based Approach for the Siemens mMR PET/MR System
  • Alteration of Monoamine Receptor Activity and Glucose Metabolism in Pediatric Patients with Anticonvulsant-Induced Cognitive Impairment
  • Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability
  • 68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis
  • Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
  • Studies of a Next-Generation Silicon-Photomultiplier–Based Time-of-Flight PET/CT System
  • Prognostic Value of Myocardial Perfusion Imaging with a Cadmium-Zinc-Telluride SPECT Camera in Patients Suspected of Having Coronary Artery Disease
  • Biodistribution and Radiation Dosimetry for the Tau Tracer 18F-THK-5351 in Healthy Human Subjects
  • Brachytherapy with Intratumoral Injections of Radiometal-Labeled Polymers That Thermoresponsively Self-Aggregate in Tumor Tissues
  • Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
  • Initial Evaluation of an Adenosine A2A Receptor Ligand, 11C-Preladenant, in Healthy Human Subjects
  • Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen
  • Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?
  • Improving Tools and Options for the Management of Patients with Neuroendocrine Tumors: A Patient Perspective
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire